Gyroscope Therapeutics, a company developing gene therapies and surgical delivery systems for retinal diseases, today announced the successful completion of a £50.4million Series B financing
• The clinical development of the company’s investigational gene therapy GT005 for dry age-related macular degeneration (dry-AMD), the leading cause of permanent vision impairment for people aged 65 and older,
• The manufacturing platform to meet patient need worldwide, and
• A second-generation Orbit Subretinal Delivery System (SDS) to not only deliver Gyroscope’s investigational
“We are grateful for the confidence Syncona and CIC have shown in Gyroscope as we continue to deliver on our promise to bring gene therapy beyond
”In addition to the Series B funding, Gyroscope also added Edward Lang Jr. to the Gyroscope Executive Committee. Mr Lang Jr. will serve as Chief Corporate Affairs Officer and brings more than 16 years of communication, public affairs and patient advocacy relations experience in the biotechnology industry from Genentech, Roche, Juno Therapeutics and Sana Biotechnology. Over his
Gyroscope: Vision for Life
Gyroscope Therapeutics is developing gene therapy beyond
Research suggests that when a part of the immune system, the complement system, is overactive it leads to inflammation that damages healthy eye tissues.
Our lead investigational therapy, GT005, is designed to restore balance to the complement system. The goal is to slow, or possibly stop the progression of dry-AMD. Patients in our ongoing Phase I/
The Orbit Subretinal Delivery System (Orbit SDS) is designed to allow surgeons to access an area of the eye called the “subretinal space” without needing to remove the vitreous (the gel-like substance that fills the eye) or make a hole in the retina. This is important as it may increase the likelihood of treatment success by delivering therapies to critical target tissues while keeping the vitreous and retina intact.
In addition to developing the Orbit SDS for delivery of our own therapies, Gyroscope will partner and license the technology to other gene and cell therapy companies.
Syncona and Cambridge Innovation Capital helped us create the only retinal gene therapy company to combine discovery research, drug development, a manufacturing platform and surgical delivery capabilities. Headquartered in London, UK, with a U.S. headquarters near Philadelphia, PA, we are building a pipeline of medicines, surgical procedures and delivery devices to preserve sight and fight the devastating impact of blindness. For more information go to www.gyroscopetx.com